Featured Research

from universities, journals, and other organizations

Young athletes with knee pain may turn to meniscus transplant

Date:
March 15, 2014
Source:
American Orthopaedic Society for Sports Medicine (AOSSM)
Summary:
Patients undergoing meniscal allograft transplantation (MAT) surgery require an additional operation approximately 32% of the time, but overall see a 95% success rate after an average five-year follow-up, according to new research.

Patients undergoing meniscal allograft transplantation (MAT) surgery require an additional operation approximately 32% of the time, but overall see a 95% success rate after an average five-year follow-up, according to new research released today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Specialty Day.

"Our research shows a positive mid to long-term outcome for patients who require MAT surgery," commented lead author Dr. Frank McCormick from Holy Cross Orthopedic Institute in Fort Lauderdale Florida, and Rush University Medical Center in Chicago. "While 64 patients out of the 172 we followed needed additional surgery, the overall survival of transplanted grafts suggests we can confidently recommend this procedure moving forward."

The study took place from January 2003 to April 2011, with patients receiving the same surgical technique as well as the same 4-6 week rehab. Follow-up surgeries included removal of tissue, equipment, and in some cases a revision of the original surgery.

"A healthy meniscus is critical to a fully functioning knee, and so also key to leading an active lifestyle," noted McCormick. "Our latest data shows that patients with damaged knees can certainly recover and return to form with the right kinds of treatment."


Story Source:

The above story is based on materials provided by American Orthopaedic Society for Sports Medicine (AOSSM). Note: Materials may be edited for content and length.


Cite This Page:

American Orthopaedic Society for Sports Medicine (AOSSM). "Young athletes with knee pain may turn to meniscus transplant." ScienceDaily. ScienceDaily, 15 March 2014. <www.sciencedaily.com/releases/2014/03/140315092907.htm>.
American Orthopaedic Society for Sports Medicine (AOSSM). (2014, March 15). Young athletes with knee pain may turn to meniscus transplant. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/03/140315092907.htm
American Orthopaedic Society for Sports Medicine (AOSSM). "Young athletes with knee pain may turn to meniscus transplant." ScienceDaily. www.sciencedaily.com/releases/2014/03/140315092907.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins